European cardiology guidelines call for routine kidney screening in heart disease patients

Europe’s heart specialists want kidney checks to become standard care

New guidance from the European Society of Cardiology argues that kidney disease screening should become routine for every patient diagnosed with cardiovascular disease, marking a notable shift in how two of the region’s biggest chronic disease burdens are managed together. The recommendations were developed with the European Renal Association and published online in the European Heart Journal, then presented at ESC Congress 2026 on August 29.

The central message is straightforward: patients with cardiovascular disease should not be treated as if heart risk exists in isolation. The guideline authors say chronic kidney disease and cardiovascular disease frequently reinforce one another, accelerating complications and raising the likelihood of serious events earlier in life. In practical terms, that means a patient entering cardiac care should also be assessed for kidney damage from the start, rather than only after symptoms become obvious or kidney function has worsened.

According to the material released alongside the guideline, chronic kidney disease affects an estimated 100 million people in Europe. The document frames that scale not only as a kidney-health problem but as a major cardiovascular challenge, because people with CKD are at elevated risk of a broad range of heart and vascular conditions. The reverse is also true: many patients already being treated for cardiovascular disease may have underdetected kidney disease that changes their prognosis and the best treatment path.

A simple screening step, but a broader care model

The new recommendation calls for screening all patients with cardiovascular disease at diagnosis for chronic kidney disease using two standard measurements: estimated glomerular filtration rate calculated from blood creatinine, and urine albumin-to-creatinine ratio. Those tests are already widely available, which is part of why the guidance matters. Rather than proposing an experimental workflow or expensive new technology, the task force is pushing for systematic use of tools that many health systems already possess.

The guideline package organizes its approach under the acronym STAMP on CKD: Screen, Triage, Address CKD Risk, Modify CVD management, and Plan health services. That structure signals that the document is not limited to testing alone. Screening is the gateway step, but the broader aim is to integrate kidney function more directly into cardiovascular decision-making.

Triage, in this framework, means using validated scoring systems that include kidney function to assess both kidney-failure risk and cardiovascular risk more accurately. The authors’ position is that conventional heart-focused management can miss important differences between patients if kidney status is treated as a secondary issue. A person with both diseases may need earlier intervention, closer monitoring, or different medication choices than someone with cardiovascular disease alone.

The “address risk” and “modify management” elements indicate the guideline’s wider ambition. The task force says recent advances have created several relatively simple treatment options that can reduce the risk of both cardiovascular and kidney complications. While the source material does not provide a full treatment algorithm, it makes clear that the guideline is built around the idea that better detection should lead to earlier and more appropriate therapy across both conditions.

Why the societies say this matters now

The release accompanying the guideline emphasizes the human and system-level cost of leaving the overlap between heart disease and kidney disease underrecognized. Task Force Chair Kevin Damman of the University Medical Center Groningen said the disability and lifetime lost to each condition are profound on their own, but that the combination can speed the arrival of cardiovascular events and dialysis. That framing helps explain why the societies are treating joint management as more than a niche specialty issue.

William Herrington of the University of Oxford, also a task force chair, said many CKD patients are already being treated within cardiology settings. The guideline therefore appears to be aimed partly at changing behavior inside cardiovascular care itself, rather than relying on kidney specialists to catch every at-risk patient later. If cardiology clinics adopt routine blood and urine screening at diagnosis, more patients could be identified before kidney impairment progresses unnoticed.

The timing also reflects a broader trend in chronic disease management: replacing siloed specialty care with risk-based pathways that recognize how major conditions interact. In this case, the ESC and the European Renal Association are making the argument that cardiovascular medicine should treat kidney health as core clinical information, not an optional add-on. That matters for frontline practice because it can influence what doctors measure, how they stratify risk, and when they escalate care.

For health systems, the “plan health services” component suggests that implementation will require more than guideline publication. Routine dual-organ risk management may affect laboratory workflows, referral pathways, digital records, and follow-up capacity. If screening expands meaningfully, providers will also need systems to interpret results consistently and connect identified patients to appropriate treatment plans.

The guideline does not claim that screening alone solves the problem. Its significance is that it sets a new expectation for standard care: heart patients should be assessed for kidney disease immediately, and the result should shape how their cardiovascular risk is understood. Given the prevalence figures cited by the societies, even incremental improvements in detection could have large downstream effects on complications, dialysis demand, and preventable cardiovascular events.

For clinicians, the recommendation is operationally simple but strategically significant. For patients, it may eventually mean that a heart diagnosis triggers a broader workup than before, including urine testing that would once have been reserved for a different specialty. And for European guideline writers, it signals a more integrated model of chronic disease management in which the boundary between cardiology and nephrology matters less than the shared risk carried by the patient.

Whether adoption is rapid will depend on national systems, reimbursement, and local practice patterns. But the policy direction from Europe’s leading cardiology body is clear: routine kidney screening in cardiovascular disease is no longer being framed as optional best practice. It is being presented as the starting point for better care.

This article is based on reporting by Medical Xpress. Read the original article.